The potential characters and rerun banners for the Genshin Impact 5.2 update have been leaked. According to the latest leaks, version 5.2 will introduce two new playable characters from Natlan ...

Players looking to summon them may be interested in the patch's banner order to plan accordingly. Luckily, Full Stop Chan recently leaked the Genshin Impact 5.2 banner order and hxg_diluc reshared ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical company down 3% in U.S. trading Wednesday. GSK, which had ...

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.